deaths (OS)

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 3 certainty unassessable-16%
cemiplimab vs. Standard of Care (SoC) 1 certainty unassessable-40%
durvalumab alone vs. Standard of Care (SoC) 1 certainty unassessable-22%
nivolumab alone vs. Standard of Care (SoC) 2 certainty unassessable+7%
pembrolizumab alone vs. Standard of Care (SoC) 4 statistically conclusive-24%